Organigram Global Inc. (NASDAQ:OGI) reported weaker second-quarter fiscal 2026 results as declining vape and infused pre-roll sales weighed on revenue and profitability. Though the Canadian cannabis producer said operational changes and its recent acquisition of Germany-based Sanity Group position the company for stronger performance in the second half of the year. • Organigram Global shares are sliding. Why are OGI shares down? Organigram Q2 Revenue Falls As Vape Sales And Margins Weaken The company reported a second-quarter loss of one cent, with sales of $43.59 million, missing the consensus of $52.06 million. Adjusted EBITDA fell 82% to $0.9 million. CEO James Yamanaka said the quarter reflected underperformance in vapes and temporary production issues in infused pre-rolls, alongside slower industry growth. "We acted quickly to address these ...Full story available on Benzinga.com